We are hosting a panel of experts to discuss Creating Digital Biomarkers with Real-World and Existing Data.

Shimmer Research Launches the Verisense Digital Health Panel to Create a Universal, Device Independent, Ground Truth Dataset to Accelerate Digital Health

Shimmer President, Geoff Gill, recently joined the More Than a Refresh podcast to talk about open-source algorithms and how wearable technology can really transform the data we collect in clinical trials.

Shimmer Americas president Geoff Gill outlines to Pharma Voice what needs to be done to transform the use of wearables in clinical trials

Shimmer Research today launched Verisense Pulse+, a new sensor for the Verisense platform. Verisense Pulse+ provides photoplethysmogram (PPG), galvanic skin response (GSR), and an inertial measurement unit (IMU). The Verisense platform can now measure clinical trial participants’ heart rate, oxygen saturation and emotional responses in addition to their activity and sleep levels.

These studies, which are funded by the American Heart Association, will use wearable sensors to increase knowledge of the links between brain and heart health.

Shimmer announced that its Verisense™ wearable sensing platform, which was developed specifically for clinical trials, has been awarded the 2020 Best of Sensors: Most Innovative Product Award in the Wearables category.

Shimmer Research, a global leader in wearable technology for research applications, today announced that its Verisense™ Inertial Measurement Unit (IMU) sensor is now a CE certified, Class I medical device (#22286).

Shimmer today announced that the Open Wearables Initiative (OWEAR) is evaluating a significant expansion of its vision and seeking industry input to build consensus.

Shimmer Research saw its Verisense™ wearable sensing platform for clinical trials feature in a peer reviewed paper, IEEE XPLORE presented at the 2020 31st Irish Signals and Systems Conference (ISSC) in June, in Letterkenny, Co. Donegal.

Shimmer will be playing a very active role in this year’s DPHARM: Disruptive Innovations US virtual conference as both a sponsor and an attendee.

Shimmer Named 2020 Citeline Award Finalist for Its Verisense™ Continuous Monitoring Platform for Clinical Trials; Co-founding Open Wearables Initiative

As Clinical Trials adapt to the much altered COVID-19 outlook, learn how the unique features of Verisense allow for seamless integration of a wearable platform into remote Clinical Trials

Read Shimmers publication on the importance of capturing raw sensor data for Clinical Studies

We understand that many people are being asked to stay home, so this is a great time to evaluate new wearable platforms for upcoming clinical research trials.

In response to the global novel coronavirus (COVID-19) pandemic, Shimmer Research continues to actively monitor any factors that may impact our ability to meet our customer’s needs.

OWEAR Founders Shimmer, GGIR software and algorithms author Dr. Vincent van Hees, and Nextbridge Health are now joined by non-profits Sage Bionetworks and DiMe

Shimmer Research is delighted to announce an exclusive interview with Worldwide Business with kathy ireland®. President Shimmer Americas, Geoffrey Gill introduces wearable sensors that help streamline clinical trials.

Shimmer Research today announced that a team of researchers from Letterkenny Institute of Technology (LYIT) and Letterkenny University Hospital (LUH) will be using Shimmer’s Verisense™ continuous monitoring platform to study fatigue accurately in individuals with breast cancer.